查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1570835

炭疽治疗药物市场：按治疗类型、给药途径、患者类型、最终用户、治疗持续时间、作用机制、疾病形式 - 全球预测 2025-2030

Anthrax Treatment Market by Treatment Type (Antibiotics, Antitoxins, Combined Therapy), Route Of Administration (Inhalational, Intravenous, Oral), Patient Type, End-User, Therapy Duration, Mechanism Of Action, Disease Form - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年炭疽治疗药物市场价值为3.8945亿美元，预计到2024年将达到4.1566亿美元，复合年增长率为7.75%，到2030年将达到6.5688亿美元。

炭疽药物是製药和医疗产业的重要组成部分，专注于控制和根除炭疽菌感染。这个市场包括各种医疗干预措施，包括Ciprofloxacin和多西环素等抗生素、新开发的抗蛇毒血清以及用于先发製人免疫和暴露后预防的疫苗。由于病原体有可能被用于生物恐怖主义，因此对有效的炭疽治疗需求更加迫切，需要强有力的准备和快速反应能力。应用主要超越医疗环境，涵盖军事、农业和公共卫生领域，凸显了对综合干预策略和产品的需求。炭疽治疗药物市场的关键成长要素包括政府增加对生物防御措施的资助、在生物恐怖主义威胁后加强公共卫生宣传活动以及提高治疗方案有效性的生物技术研究的进步。速效、频谱治疗的创新以及减少副作用和延长免疫力的疫苗配方的开发存在潜在的机会。生物技术公司、学术机构和政府机构之间的合作将为创新提供肥沃的土壤，确保与动态监管标准保持一致，并利用人工智慧等技术进行快速药物开发。然而，市场成长面临高昂的研发成本、监管核准的复杂性以及炭疽菌自然爆发的罕见性等挑战，限制了重大投资的理由。此外，大众对疫苗相关副作用的担忧也是另一个障碍。最具创新潜力的领域包括开发对抗抗生素抗药性的双效疗法、新型疫苗输送系统以及用于快速发现和开始治疗的改进诊断工具。市场本质上是由必要性和紧急准备驱动的，而对研究和策略伙伴关係关係的关注对于在这些挑战中推动永续成长至关重要。

主要市场统计
基准年[2023] 38945万美元
预测年份 [2024] 41566万美元
预测年份 [2030] 65688万美元
复合年增长率（%） 7.75%

市场动态：揭示快速发展的炭疽药物市场的关键市场洞察

供需的动态交互作用正在改变炭疽药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助组织降低政治、地理、技术、社会和经济领域的风险，以及消费行为及其对製造成本的影响及其对采购趋势的影响。

波特的五力：驾驭炭疽药物市场的策略工具

波特的五力架构是了解炭疽治疗药物市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解炭疽药物市场的外部影响

外部宏观环境因素在塑造炭疽治疗药物市场的表现动态中发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解炭疽药物市场的竞争状况

对炭疽治疗药物市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵炭疽治疗市场供应商的绩效评估

FPNV定位矩阵是评估炭疽治疗市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议，以规划炭疽治疗药物市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对炭疽治疗药物市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

该报告提供了涵盖主要焦点细分市场的全面市场分析。

1. 市场渗透率：对当前市场环境的详细回顾。

2. 市场开拓：辨识新兴市场的成长机会，评估现有产业的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检视市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 扩大以感染疾病治疗为重点的生物技术和製药业
      • 人们越来越需要有效、快速起效的治疗方法来控制炭疽症状。
      • 加强发展中地区的卫生基础设施以管理感染疾病爆发
      • 用于开发炭疽菌疫苗和治疗方法的公共和私人资金
    • 抑制因素
      • 发展中地区的认知和医疗基础设施有限限制了炭疽药物的市场渗透。
      • 维持疫苗分销低温运输物流的挑战 炭疽治疗市场
    • 机会
      • 对先进生物恐怖主义对策和紧急应变准备的需求不断增加
      • 将人工智慧融入标靶炭疽药物解决方案的开发
      • 改善医疗基础设施，使发展中地区获得有效的炭疽菌治疗
    • 任务
      • 新兴市场的炭疽菌意识和诊断能力有限，影响了治疗效果
      • 供应链中断影响炭疽治疗方案的可用性和可近性
  • 市场区隔分析
  • 波特五力分析
  • PESTLE分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章炭疽治疗药物市场：依治疗类型

  • 介绍
  • 抗生素
    • Ciprofloxacin
    • 强力霉素
    • levofloxacin
    • 青霉素
  • 抗毒素
    • 奥比妥沙昔单抗
    • 拉西巴库单抗
  • 联合治疗
    • 抗生素和抗毒素

第七章炭疽治疗市场：依给药途径

  • 介绍
  • 吸入
  • 静脉
  • 口服
  • 皮下的

第八章炭疽治疗药物市场：依患者类型

  • 介绍
  • 成人
  • 老年人
  • 儿科的

第九章炭疽治疗药物市场：依最终使用者分类

  • 介绍
  • 门诊手术中心
  • 诊所
  • 居家医疗
  • 医院

第10章炭疽治疗药物市场：依治疗持续时间

  • 介绍
  • 长期治疗
    • 4週或以上
  • 短期治疗
    • 2-4週
    • 2週或更短时间

第十一章炭疽药物市场：按作用机制

  • 介绍
  • 杀菌作用
  • 细菌停滞

第十二章炭疽治疗市场：依疾病类型

  • 介绍
  • 皮肤炭疽病
  • 胃肠道炭疽
  • 吸入性炭疽
  • 注射炭疽菌

第十三章美洲炭疽药物市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十四章亚太炭疽药物市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十五章 欧洲、中东和非洲炭疽药物市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十六章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争场景分析
  • 战略分析和建议
Product Code: MRR-1A1A064C0102

The Anthrax Treatment Market was valued at USD 389.45 million in 2023, expected to reach USD 415.66 million in 2024, and is projected to grow at a CAGR of 7.75%, to USD 656.88 million by 2030.

Anthrax treatment is a critical segment within the pharmaceutical and healthcare industries, concentrating on the management and eradication of Bacillus anthracis infections. This market's scope encompasses various medical interventions, including antibiotics like ciprofloxacin, doxycycline, and newly developed antitoxins and vaccines aimed at preemptive immunization and post-exposure prophylaxis. The necessity for effective anthrax treatment is heightened due to the potential use of the pathogen in bioterrorism, demanding robust preparedness and rapid response capabilities. Applications chiefly transcend healthcare settings, encompassing military, agricultural, and public health domains, highlighting the need for comprehensive intervention strategies and products. Key growth influencers in the anthrax treatment market include increased government funding for biodefense measures, heightened public health campaigns post-bioterror threats, and advancements in biotechnological research enhancing the efficacy of treatment options. Potential opportunities lie in innovating fast-acting, broad-spectrum therapeutics and developing vaccine formulations that offer prolonged immunity with reduced side-effects. Encouragingly, collaborations among biotech firms, academia, and governmental bodies present a fertile ground for innovation, ensuring alignment with dynamic regulatory standards and leveraging technological advancements like AI for rapid drug development. However, market growth is challenged by factors such as the high cost of R&D, complexities associated with regulatory approvals, and the rarity of natural anthrax occurrences, which constrain the justification for substantial investment. Furthermore, public apprehensions regarding vaccine-related adverse effects pose additional hurdles. The most promising areas for innovation include the development of dual-action therapeutics that address antibiotic resistance, novel vaccine delivery systems, and improved diagnostic tools for rapid detection and treatment initiation. The market is inherently driven by necessity and emergency preparedness, with its focus on research and strategic partnerships being quintessential to facilitate sustainable growth amidst these challenges.

KEY MARKET STATISTICS
Base Year [2023] USD 389.45 million
Estimated Year [2024] USD 415.66 million
Forecast Year [2030] USD 656.88 million
CAGR (%) 7.75%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Anthrax Treatment Market

The Anthrax Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Expansion of biotechnology and pharmaceutical industries focusing on infectious disease treatments
    • Growing demand for effective and fast-acting treatments to manage anthrax symptoms
    • Enhanced healthcare infrastructure in developing regions to manage infectious disease outbreaks
    • Public and private funding for the development of vaccines and treatments for anthrax
  • Market Restraints
    • Limited awareness and healthcare infrastructure in developing regions restricts market penetration for anthrax treatment
    • Challenges in maintaining cold chain logistics for vaccine distribution in the anthrax treatment market
  • Market Opportunities
    • Rising demand for advanced bioterrorism countermeasures and emergency response preparedness
    • Integration of artificial intelligence in developing targeted anthrax treatment solutions
    • Improvement in healthcare infrastructure enabling access to effective anthrax treatments in developing regions
  • Market Challenges
    • Limited awareness and diagnosis capabilities for anthrax in emerging markets impacting treatment efficacy
    • Supply chain disruptions affecting the availability and accessibility of anthrax treatment options

Porter's Five Forces: A Strategic Tool for Navigating the Anthrax Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Anthrax Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Anthrax Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Anthrax Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Anthrax Treatment Market

A detailed market share analysis in the Anthrax Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Anthrax Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Anthrax Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Anthrax Treatment Market

A strategic analysis of the Anthrax Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anthrax Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Altimmune, AstraZeneca, Bayer HealthCare, Cipla, Elusys Therapeutics, Emergent BioSolutions, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Lupin Pharmaceuticals, Merck & Co., Mylan, Novartis, Paratek Pharmaceuticals, Pfizer, PharmAthene, Roche, Sanofi, and Teva Pharmaceutical Industries.

Market Segmentation & Coverage

This research report categorizes the Anthrax Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment Type, market is studied across Antibiotics, Antitoxins, and Combined Therapy. The Antibiotics is further studied across Ciprofloxacin, Doxycycline, Levofloxacin, and Penicillin. The Antitoxins is further studied across Obiltoxaximab and Raxibacumab. The Combined Therapy is further studied across Antibiotics And Antitoxins.
  • Based on Route Of Administration, market is studied across Inhalational, Intravenous, Oral, and Subcutaneous.
  • Based on Patient Type, market is studied across Adult, Geriatric, and Pediatric.
  • Based on End-User, market is studied across Ambulatory Surgery Centers, Clinics, Homecare Settings, and Hospitals.
  • Based on Therapy Duration, market is studied across Long-Term Therapy and Short-Term Therapy. The Long-Term Therapy is further studied across More Than 4 Weeks. The Short-Term Therapy is further studied across 2 To 4 Weeks and Less Than 2 Weeks.
  • Based on Mechanism Of Action, market is studied across Bactericidal and Bacteriostatic.
  • Based on Disease Form, market is studied across Cutaneous Anthrax, Gastrointestinal Anthrax, Inhalation Anthrax, and Injection Anthrax.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Expansion of biotechnology and pharmaceutical industries focusing on infectious disease treatments
      • 5.1.1.2. Growing demand for effective and fast-acting treatments to manage anthrax symptoms
      • 5.1.1.3. Enhanced healthcare infrastructure in developing regions to manage infectious disease outbreaks
      • 5.1.1.4. Public and private funding for the development of vaccines and treatments for anthrax
    • 5.1.2. Restraints
      • 5.1.2.1. Limited awareness and healthcare infrastructure in developing regions restricts market penetration for anthrax treatment
      • 5.1.2.2. Challenges in maintaining cold chain logistics for vaccine distribution in the anthrax treatment market
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising demand for advanced bioterrorism countermeasures and emergency response preparedness
      • 5.1.3.2. Integration of artificial intelligence in developing targeted anthrax treatment solutions
      • 5.1.3.3. Improvement in healthcare infrastructure enabling access to effective anthrax treatments in developing regions
    • 5.1.4. Challenges
      • 5.1.4.1. Limited awareness and diagnosis capabilities for anthrax in emerging markets impacting treatment efficacy
      • 5.1.4.2. Supply chain disruptions affecting the availability and accessibility of anthrax treatment options
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Anthrax Treatment Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Antibiotics
    • 6.2.1. Ciprofloxacin
    • 6.2.2. Doxycycline
    • 6.2.3. Levofloxacin
    • 6.2.4. Penicillin
  • 6.3. Antitoxins
    • 6.3.1. Obiltoxaximab
    • 6.3.2. Raxibacumab
  • 6.4. Combined Therapy
    • 6.4.1. Antibiotics And Antitoxins

7. Anthrax Treatment Market, by Route Of Administration

  • 7.1. Introduction
  • 7.2. Inhalational
  • 7.3. Intravenous
  • 7.4. Oral
  • 7.5. Subcutaneous

8. Anthrax Treatment Market, by Patient Type

  • 8.1. Introduction
  • 8.2. Adult
  • 8.3. Geriatric
  • 8.4. Pediatric

9. Anthrax Treatment Market, by End-User

  • 9.1. Introduction
  • 9.2. Ambulatory Surgery Centers
  • 9.3. Clinics
  • 9.4. Homecare Settings
  • 9.5. Hospitals

10. Anthrax Treatment Market, by Therapy Duration

  • 10.1. Introduction
  • 10.2. Long-Term Therapy
    • 10.2.1. More Than 4 Weeks
  • 10.3. Short-Term Therapy
    • 10.3.1. 2 To 4 Weeks
    • 10.3.2. Less Than 2 Weeks

11. Anthrax Treatment Market, by Mechanism Of Action

  • 11.1. Introduction
  • 11.2. Bactericidal
  • 11.3. Bacteriostatic

12. Anthrax Treatment Market, by Disease Form

  • 12.1. Introduction
  • 12.2. Cutaneous Anthrax
  • 12.3. Gastrointestinal Anthrax
  • 12.4. Inhalation Anthrax
  • 12.5. Injection Anthrax

13. Americas Anthrax Treatment Market

  • 13.1. Introduction
  • 13.2. Argentina
  • 13.3. Brazil
  • 13.4. Canada
  • 13.5. Mexico
  • 13.6. United States

14. Asia-Pacific Anthrax Treatment Market

  • 14.1. Introduction
  • 14.2. Australia
  • 14.3. China
  • 14.4. India
  • 14.5. Indonesia
  • 14.6. Japan
  • 14.7. Malaysia
  • 14.8. Philippines
  • 14.9. Singapore
  • 14.10. South Korea
  • 14.11. Taiwan
  • 14.12. Thailand
  • 14.13. Vietnam

15. Europe, Middle East & Africa Anthrax Treatment Market

  • 15.1. Introduction
  • 15.2. Denmark
  • 15.3. Egypt
  • 15.4. Finland
  • 15.5. France
  • 15.6. Germany
  • 15.7. Israel
  • 15.8. Italy
  • 15.9. Netherlands
  • 15.10. Nigeria
  • 15.11. Norway
  • 15.12. Poland
  • 15.13. Qatar
  • 15.14. Russia
  • 15.15. Saudi Arabia
  • 15.16. South Africa
  • 15.17. Spain
  • 15.18. Sweden
  • 15.19. Switzerland
  • 15.20. Turkey
  • 15.21. United Arab Emirates
  • 15.22. United Kingdom

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2023
  • 16.2. FPNV Positioning Matrix, 2023
  • 16.3. Competitive Scenario Analysis
  • 16.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Altimmune
  • 3. AstraZeneca
  • 4. Bayer HealthCare
  • 5. Cipla
  • 6. Elusys Therapeutics
  • 7. Emergent BioSolutions
  • 8. Gilead Sciences
  • 9. GlaxoSmithKline
  • 10. Johnson & Johnson
  • 11. Lupin Pharmaceuticals
  • 12. Merck & Co.
  • 13. Mylan
  • 14. Novartis
  • 15. Paratek Pharmaceuticals
  • 16. Pfizer
  • 17. PharmAthene
  • 18. Roche
  • 19. Sanofi
  • 20. Teva Pharmaceutical Industries

LIST OF FIGURES

  • FIGURE 1. ANTHRAX TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. ANTHRAX TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTHRAX TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY PATIENT TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY PATIENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY THERAPY DURATION, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY THERAPY DURATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY DISEASE FORM, 2023 VS 2030 (%)
  • FIGURE 19. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY DISEASE FORM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. AMERICAS ANTHRAX TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. AMERICAS ANTHRAX TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. UNITED STATES ANTHRAX TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 23. UNITED STATES ANTHRAX TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC ANTHRAX TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. ASIA-PACIFIC ANTHRAX TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 28. ANTHRAX TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 29. ANTHRAX TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTHRAX TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTHRAX TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTHRAX TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY CIPROFLOXACIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY DOXYCYCLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY LEVOFLOXACIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY PENICILLIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY OBILTOXAXIMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY RAXIBACUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXINS, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY COMBINED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTICS AND ANTITOXINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY COMBINED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY INHALATIONAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY MORE THAN 4 WEEKS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY 2 TO 4 WEEKS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY LESS THAN 2 WEEKS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY BACTERICIDAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY BACTERIOSTATIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY DISEASE FORM, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY CUTANEOUS ANTHRAX, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY GASTROINTESTINAL ANTHRAX, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY INHALATION ANTHRAX, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY INJECTION ANTHRAX, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS ANTHRAX TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXINS, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS ANTHRAX TREATMENT MARKET SIZE, BY COMBINED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS ANTHRAX TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS ANTHRAX TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS ANTHRAX TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS ANTHRAX TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS ANTHRAX TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS ANTHRAX TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS ANTHRAX TREATMENT MARKET SIZE, BY DISEASE FORM, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS ANTHRAX TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA ANTHRAX TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXINS, 2018-2030 (USD MILLION)
  • TABLE 67. ARGENTINA ANTHRAX TREATMENT MARKET SIZE, BY COMBINED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA ANTHRAX TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA ANTHRAX TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA ANTHRAX TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA ANTHRAX TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA ANTHRAX TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 74. ARGENTINA ANTHRAX TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 75. ARGENTINA ANTHRAX TREATMENT MARKET SIZE, BY DISEASE FORM, 2018-2030 (USD MILLION)
  • TABLE 76. BRAZIL ANTHRAX TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. BRAZIL ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 78. BRAZIL ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXINS, 2018-2030 (USD MILLION)
  • TABLE 79. BRAZIL ANTHRAX TREATMENT MARKET SIZE, BY COMBINED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 80. BRAZIL ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. BRAZIL ANTHRAX TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL ANTHRAX TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. BRAZIL ANTHRAX TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 84. BRAZIL ANTHRAX TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 85. BRAZIL ANTHRAX TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 86. BRAZIL ANTHRAX TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 87. BRAZIL ANTHRAX TREATMENT MARKET SIZE, BY DISEASE FORM, 2018-2030 (USD MILLION)
  • TABLE 88. CANADA ANTHRAX TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. CANADA ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 90. CANADA ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXINS, 2018-2030 (USD MILLION)
  • TABLE 91. CANADA ANTHRAX TREATMENT MARKET SIZE, BY COMBINED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 92. CANADA ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. CANADA ANTHRAX TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. CANADA ANTHRAX TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. CANADA ANTHRAX TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 96. CANADA ANTHRAX TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 97. CANADA ANTHRAX TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 98. CANADA ANTHRAX TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 99. CANADA ANTHRAX TREATMENT MARKET SIZE, BY DISEASE FORM, 2018-2030 (USD MILLION)
  • TABLE 100. MEXICO ANTHRAX TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. MEXICO ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 102. MEXICO ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXINS, 2018-2030 (USD MILLION)
  • TABLE 103. MEXICO ANTHRAX TREATMENT MARKET SIZE, BY COMBINED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 104. MEXICO ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. MEXICO ANTHRAX TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. MEXICO ANTHRAX TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. MEXICO ANTHRAX TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 108. MEXICO ANTHRAX TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 109. MEXICO ANTHRAX TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 110. MEXICO ANTHRAX TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 111. MEXICO ANTHRAX TREATMENT MARKET SIZE, BY DISEASE FORM, 2018-2030 (USD MILLION)
  • TABLE 112. UNITED STATES ANTHRAX TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. UNITED STATES ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 114. UNITED STATES ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXINS, 2018-2030 (USD MILLION)
  • TABLE 115. UNITED STATES ANTHRAX TREATMENT MARKET SIZE, BY COMBINED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 116. UNITED STATES ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. UNITED STATES ANTHRAX TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. UNITED STATES ANTHRAX TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. UNITED STATES ANTHRAX TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 120. UNITED STATES ANTHRAX TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 121. UNITED STATES ANTHRAX TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 122. UNITED STATES ANTHRAX TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 123. UNITED STATES ANTHRAX TREATMENT MARKET SIZE, BY DISEASE FORM, 2018-2030 (USD MILLION)
  • TABLE 124. UNITED STATES ANTHRAX TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC ANTHRAX TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXINS, 2018-2030 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC ANTHRAX TREATMENT MARKET SIZE, BY COMBINED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC ANTHRAX TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC ANTHRAX TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC ANTHRAX TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC ANTHRAX TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC ANTHRAX TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC ANTHRAX TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC ANTHRAX TREATMENT MARKET SIZE, BY DISEASE FORM, 2018-2030 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC ANTHRAX TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 138. AUSTRALIA ANTHRAX TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. AUSTRALIA ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 140. AUSTRALIA ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXINS, 2018-2030 (USD MILLION)
  • TABLE 141. AUSTRALIA ANTHRAX TREATMENT MARKET SIZE, BY COMBINED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 142. AUSTRALIA ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. AUSTRALIA ANTHRAX TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. AUSTRALIA ANTHRAX TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. AUSTRALIA ANTHRAX TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 146. AUSTRALIA ANTHRAX TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 147. AUSTRALIA ANTHRAX TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 148. AUSTRALIA ANTHRAX TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 149. AUSTRALIA ANTHRAX TREATMENT MARKET SIZE, BY DISEASE FORM, 2018-2030 (USD MILLION)
  • TABLE 150. CHINA ANTHRAX TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. CHINA ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 152. CHINA ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXINS, 2018-2030 (USD MILLION)
  • TABLE 153. CHINA ANTHRAX TREATMENT MARKET SIZE, BY COMBINED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 154. CHINA ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. CHINA ANTHRAX TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. CHINA ANTHRAX TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 157. CHINA ANTHRAX TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 158. CHINA ANTHRAX TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 159. CHINA ANTHRAX TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 160. CHINA ANTHRAX TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 161. CHINA ANTHRAX TREATMENT MARKET SIZE, BY DISEASE FORM, 2018-2030 (USD MILLION)
  • TABLE 162. INDIA ANTHRAX TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. INDIA ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 164. INDIA ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXINS, 2018-2030 (USD MILLION)
  • TABLE 165. INDIA ANTHRAX TREATMENT MARKET SIZE, BY COMBINED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 166. INDIA ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 167. INDIA ANTHRAX TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. INDIA ANTHRAX TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 169. INDIA ANTHRAX TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 170. INDIA ANTHRAX TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 171. INDIA ANTHRAX TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 172. INDIA ANTHRAX TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 173. INDIA ANTHRAX TREATMENT MARKET SIZE, BY DISEASE FORM, 2018-2030 (USD MILLION)
  • TABLE 174. INDONESIA ANTHRAX TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. INDONESIA ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 176. INDONESIA ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXINS, 2018-2030 (USD MILLION)
  • TABLE 177. INDONESIA ANTHRAX TREATMENT MARKET SIZE, BY COMBINED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 178. INDONESIA ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. INDONESIA ANTHRAX TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. INDONESIA ANTHRAX TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 181. INDONESIA ANTHRAX TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 182. INDONESIA ANTHRAX TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 183. INDONESIA ANTHRAX TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 184. INDONESIA ANTHRAX TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 185. INDONESIA ANTHRAX TREATMENT MARKET SIZE, BY DISEASE FORM, 2018-2030 (USD MILLION)
  • TABLE 186. JAPAN ANTHRAX TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. JAPAN ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 188. JAPAN ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXINS, 2018-2030 (USD MILLION)
  • TABLE 189. JAPAN ANTHRAX TREATMENT MARKET SIZE, BY COMBINED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 190. JAPAN ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 191. JAPAN ANTHRAX TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. JAPAN ANTHRAX TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 193. JAPAN ANTHRAX TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 194. JAPAN ANTHRAX TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 195. JAPAN ANTHRAX TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 196. JAPAN ANTHRAX TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 197. JAPAN ANTHRAX TREATMENT MARKET SIZE, BY DISEASE FORM, 2018-2030 (USD MILLION)
  • TABLE 198. MALAYSIA ANTHRAX TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. MALAYSIA ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 200. MALAYSIA ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXINS, 2018-2030 (USD MILLION)
  • TABLE 201. MALAYSIA ANTHRAX TREATMENT MARKET SIZE, BY COMBINED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 202. MALAYSIA ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 203. MALAYSIA ANTHRAX TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. MALAYSIA ANTHRAX TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 205. MALAYSIA ANTHRAX TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 206. MALAYSIA ANTHRAX TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 207. MALAYSIA ANTHRAX TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 208. MALAYSIA ANTHRAX TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 209. MALAYSIA ANTHRAX TREATMENT MARKET SIZE, BY DISEASE FORM, 2018-2030 (USD MILLION)
  • TABLE 210. PHILIPPINES ANTHRAX TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. PHILIPPINES ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 212. PHILIPPINES ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXINS, 2018-2030 (USD MILLION)
  • TABLE 213. PHILIPPINES ANTHRAX TREATMENT MARKET SIZE, BY COMBINED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 214. PHILIPPINES ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 215. PHILIPPINES ANTHRAX TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. PHILIPPINES ANTHRAX TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 217. PHILIPPINES ANTHRAX TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 218. PHILIPPINES ANTHRAX TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 219. PHILIPPINES ANTHRAX TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 220. PHILIPPINES ANTHRAX TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 221. PHILIPPINES ANTHRAX TREATMENT MARKET SIZE, BY DISEASE FORM, 2018-2030 (USD MILLION)
  • TABLE 222. SINGAPORE ANTHRAX TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. SINGAPORE ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 224. SINGAPORE ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXINS, 2018-2030 (USD MILLION)
  • TABLE 225. SINGAPORE ANTHRAX TREATMENT MARKET SIZE, BY COMBINED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 226. SINGAPORE ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 227. SINGAPORE ANTHRAX TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. SINGAPORE ANTHRAX TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 229. SINGAPORE ANTHRAX TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 230. SINGAPORE ANTHRAX TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 231. SINGAPORE ANTHRAX TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 232. SINGAPORE ANTHRAX TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 233. SINGAPORE ANTHRAX TREATMENT MARKET SIZE, BY DISEASE FORM, 2018-2030 (USD MILLION)
  • TABLE 234. SOUTH KOREA ANTHRAX TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. SOUTH KOREA ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 236. SOUTH KOREA ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXINS, 2018-2030 (USD MILLION)
  • TABLE 237. SOUTH KOREA ANTHRAX TREATMENT MARKET SIZE, BY COMBINED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 238. SOUTH KOREA ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 239. SOUTH KOREA ANTHRAX TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. SOUTH KOREA ANTHRAX TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH KOREA ANTHRAX TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH KOREA ANTHRAX TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH KOREA ANTHRAX TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH KOREA ANTHRAX TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH KOREA ANTHRAX TREATMENT MARKET SIZE, BY DISEASE FORM, 2018-2030 (USD MILLION)
  • TABLE 246. TAIWAN ANTHRAX TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 247. TAIWAN ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 248. TAIWAN ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXINS, 2018-2030 (USD MILLION)
  • TABLE 249. TAIWAN ANTHRAX TREATMENT MARKET SIZE, BY COMBINED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 250. TAIWAN ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 251. TAIWAN ANTHRAX TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 252. TAIWAN ANTHRAX TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 253. TAIWAN ANTHRAX TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 254. TAIWAN ANTHRAX TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 255. TAIWAN ANTHRAX TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 256. TAIWAN ANTHRAX TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 257. TAIWAN ANTHRAX TREATMENT MARKET SIZE, BY DISEASE FORM, 2018-2030 (USD MILLION)
  • TABLE 258. THAILAND ANTHRAX TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 259. THAILAND ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 260. THAILAND ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXINS, 2018-2030 (USD MILLION)
  • TABLE 261. THAILAND ANTHRAX TREATMENT MARKET SIZE, BY COMBINED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 262. THAILAND ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 263. THAILAND ANTHRAX TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 264. THAILAND ANTHRAX TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 265. THAILAND ANTHRAX TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 266. THAILAND ANTHRAX TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 267. THAILAND ANTHRAX TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 268. THAILAND ANTHRAX TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 269. THAILAND ANTHRAX TREATMENT MARKET SIZE, BY DISEASE FORM, 2018-2030 (USD MILLION)
  • TABLE 270. VIETNAM ANTHRAX TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 271. VIETNAM ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 272. VIETNAM ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXINS, 2018-2030 (USD MILLION)
  • TABLE 273. VIETNAM ANTHRAX TREATMENT MARKET SIZE, BY COMBINED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 274. VIETNAM ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 275. VIETNAM ANTHRAX TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 276. VIETNAM ANTHRAX TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 277. VIETNAM ANTHRAX TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 278. VIETNAM ANTHRAX TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 279. VIETNAM ANTHRAX TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 280. VIETNAM ANTHRAX TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 281. VIETNAM ANTHRAX TREATMENT MARKET SIZE, BY DISEASE FORM, 2018-2030 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXINS, 2018-2030 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET SIZE, BY COMBINED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET SIZE, BY DISEASE FORM, 2018-2030 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 295. DENMARK ANTHRAX TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 296. DENMARK ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 297. DENMARK ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXINS, 2018-2030 (USD MILLION)
  • TABLE 298. DENMARK ANTHRAX TREATMENT MARKET SIZE, BY COMBINED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 299. DENMARK ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 300. DENMARK ANTHRAX TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 301. DENMARK ANTHRAX TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 302. DENMARK ANTHRAX TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 303. DENMARK ANTHRAX TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 304. DENMARK ANTHRAX TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 305. DENMARK ANTHRAX TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 306. DENMARK ANTHRAX TREATMENT MARKET SIZE, BY DISEASE FORM, 2018-2030 (USD MILLION)
  • TABLE 307. EGYPT ANTHRAX TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 308. EGYPT ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 309. EGYPT ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXINS, 2018-2030 (USD MILLION)
  • TABLE 310. EGYPT ANTHRAX TREATMENT MARKET SIZE, BY COMBINED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 311. EGYPT ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 312. EGYPT ANTHRAX TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 313. EGYPT ANTHRAX TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 314. EGYPT ANTHRAX TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 315. EGYPT ANTHRAX TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 316. EGYPT ANTHRAX TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 317. EGYPT ANTHRAX TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 318. EGYPT ANTHRAX TREATMENT MARKET SIZE, BY DISEASE FORM, 2018-2030 (USD MILLION)
  • TABLE 319. FINLAND ANTHRAX TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 320. FINLAND ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 321. FINLAND ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXINS, 2018-2030 (USD MILLION)
  • TABLE 322. FINLAND ANTHRAX TREATMENT MARKET SIZE, BY COMBINED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 323. FINLAND ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 324. FINLAND ANTHRAX TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 325. FINLAND ANTHRAX TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 326. FINLAND ANTHRAX TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 327. FINLAND ANTHRAX TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 328. FINLAND ANTHRAX TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 329. FINLAND ANTHRAX TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 330. FINLAND ANTHRAX TREATMENT MARKET SIZE, BY DISEASE FORM, 2018-2030 (USD MILLION)
  • TABLE 331. FRANCE ANTHRAX TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 332. FRANCE ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 333. FRANCE ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXINS, 2018-2030 (USD MILLION)
  • TABLE 334. FRANCE ANTHRAX TREATMENT MARKET SIZE, BY COMBINED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 335. FRANCE ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 336. FRANCE ANTHRAX TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 337. FRANCE ANTHRAX TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 338. FRANCE ANTHRAX TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 339. FRANCE ANTHRAX TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 340. FRANCE ANTHRAX TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 341. FRANCE ANTHRAX TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 342. FRANCE ANTHRAX TREATMENT MARKET SIZE, BY DISEASE FORM, 2018-2030 (USD MILLION)
  • TABLE 343. GERMANY ANTHRAX TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 344. GERMANY ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 345. GERMANY ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXINS, 2018-2030 (USD MI